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Abstract
Five point mutations (R88H, R88P, T118I, 959delT, R468Q) previously identified in the iduronate-2-sulfatase (IDS) gene
of Italian Hunter patients were expressed in COS cells to evaluate their functional consequence on enzyme activity,
processing and intracellular localization. The 88 arginine residue belongs to the CXPSR pentapeptide conserved in all human
sulfatases, where cysteine modification to formylglycine is required for enzyme activity. Substitution of arginine with
histidine residue resulted in 13.7% residual enzyme activity, with an apparent Km value (133 WM) lower than that found for
the normal enzyme (327 WM), indicating a higher affinity for the substrate; substitution of arginine with proline resulted in
total absence of residual activity, in agreement with the phenotypes observed in patients carrying R88H and R88P mutations.
For the four missense mutations, pulse-chase labelling experiments showed an apparently normal maturation; however,
subcellular fractionation demonstrated poor transport to lysosomes. Therefore, residues 88, 118 and 468 appear to be not
essential for processing but important for IDS conformation. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Iduronate-2-sulfatase (IDS) (EC 3.1.6.13.) is a ly-
sosomal enzyme involved in the catabolism of muco-
polysaccharides heparan sulfate and dermatan sul-
fate; its de¢ciency causes mucopolysaccharidosis
type II (MPS II), Hunter syndrome, an X-linked re-
cessive disorder characterized by a wide spectrum of
clinical severity ranging from mild to severe forms
[1].
The IDS gene has been cloned and characterized
[2^4]; it contains nine exons spread over 24 kilobases
and located on the Xq27/28 boundary of the long
arm of the X-chromosome. The IDS full-length
cDNA encodes a polypeptide of 550 amino acids
which shows a high degree of homology with the
sulfatase protein family [2]. The biosynthesis and
processing of the IDS protein have been studied in
overexpressing transfected ¢broblasts; the enzyme is
synthesized as two precursor forms of 76 and 90 kDa
that are converted, through a 62 kDa intermediate,
to 55 and 45 kDa mature polypeptides [5,6].
Molecular defects in the IDS gene (for review see
[7]) have been identi¢ed in many laboratories ac-
counting, at present, for approximately 200 small
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mutations. However, probably due to technical di⁄-
culties, only 13 alterations have been studied through
site-directed mutagenesis and in vitro expression; of
these, nine have been expressed in deleted ¢broblasts
[8,9] and four in COS cells [10].
We have analyzed several Italian patients in the
past [11,12] and more recently, revealing a IDS struc-
tural alteration with production of aberrant mRNA
species [13,14] and identifying 16 point mutations, 10
novel [15,16]. In this study, we reproduced ¢ve of the
identi¢ed mutations (R88H, R88P, T118I, 959delT
and R468Q) by in vitro site-directed mutagenesis in
order to evaluate their functional consequence on
IDS activity, processing and enzyme localization.
2. Materials and methods
2.1. Site-directed mutagenesis
The full-length IDS cDNA clone was kindly pro-
vided by Prof. Myazaki and Tomatsu (Gifu Univer-
sity, Japan). IDS expression plasmid pCAGGS-IDS
[17] was mutagenized using the commercially avail-
able Transformer II kit (Clontech) according to the
manufacturer’s instructions. Brie£y, as described by
Deng and Nickolo¡ [18], the mutagenic primer (the
point mutation primer) and the ‘selection’ primer,
which mutates the SalI unique site in pCGGAS to
a XhoI site, were annealed to double stranded
pCAGGS DNA. The mutant DNA strand was syn-
thesized and the parental DNA was linearized by
digestion with SalI for 2 h. 2 Wl of the reaction mix-
ture was used to transform Escherichia coli mut S
cells. These were grown in 5 ml LB medium over-
night in the presence of Ampicillin, to enrich for mu-
tant plasmids. Miniprep DNA was isolated using the
alkali lysis procedure [19], subjected to a second
round of digestion with SalI, transformed into
E. coli XL1-blue cells and grown on plates overnight.
The resulting colonies were screened for the absence
of the SalI site by restriction digest analysis and then
sequenced to verify the presence of point mutations.
To introduce mutations R88H, R88P, T118I,
959delT (previously named L279nt31) and R468Q
into wild-type IDS cDNA, the following oligo-
nucleotides were used: (5P-CCCCGAGCCACGT-
TTCTT TCC, R88H); (5P-CCCCGAGCCCCGTT-
TCTTTCC, R88P); (5P-GAAACTTCTCCATCAT-
CCCCC, T118I); (5P-CGTCCAAGCCT_AAACAT-
CAG, 959delT); (5P-CAGTATCCCCTGCCTTCA-
GAC, R468Q); selection primer was: 5P-GTGC-
CACCTGGCTCGAGATTGATTATTGA.
2.2. COS 7 cells transfection and protein extracts
COS 7 cells were grown in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) supplemented with 10%
FCS, 100 Wg/ml penicillin, 100 Wg/ml streptomycin
at 37‡C in a 5% CO2/air atmosphere. 10 Wg of
wild-type and mutant cDNA expression vector con-
structs were introduced into COS 7 cells by electro-
poration. The experimental conditions were: 4^
5U106 cells in a ¢nal volume of 800 Wl PBS without
Ca2/Mg2, 10 Wg of plasmid DNA, one shot at 1200
V, 25 WF, in a Bio-Rad Gene Pulser apparatus. Cells
were seeded in 100 mm2 Petri dishes and then har-
vested 24^48 h after transfection, washed twice with
150 mM NaCl, resuspended in the same bu¡er and
frozen-thawed six times. All transfections were per-
formed in triplicate. Each triplicate was assayed for
total protein content using the Lowry assay [20]. As
control for transfection e⁄ciency, 2 Wg of a construct
carrying a luciferase reporter gene under the control
of a strong cytomegalovirus promoter was cotrans-
fected.
2.3. Enzyme analysis
To test for IDS activity, the cellular extracts were
dialyzed overnight against 4 l of 150 mM NaCl. IDS
assay was performed by incubating 30 Wg of proteins
for 2 h with the radiolabeled disaccharide substrate,
O-(K-L-idopyranosyluronic acid-2-sulfate)-(1C4)-2,5
anhydromannose-6-sulfate, as described previously
[21,12]. One unit of enzymatic activity represents
the amount of enzyme that hydrolyzes 1% 3H sub-
strate per hour.
Kinetic parameters were obtained by incubation of
40 Wg of proteins, derived from wild-type or R88H
mutant cell extracts, with ¢ve di¡erent concentra-
tions of substrate, ranging from 14 to 75 WM. Km
and Vmax were calculated from Lineweaver^Burk
plots.
Luciferase activity was tested by a bioluminescent
assay as described elsewhere [22]. L-Hexosaminidase
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(L-N-acetylglucosaminidase) activity was determined
by £uorescent assay using 4-methylumbelliferyl-N-
acetyl-L-D-glucosaminide as arti¢cial substrate, ac-
cording to Geiger and Arnon [23].
2.4. Recombinant IDS and production of polyclonal
antibodies
The cDNA region encoding amino acids 323^550
of IDS was fused to the six-histidine tag bacterial
expression vector pQE (QIAGEN) and produced in
E. coli after induction with IPTG. The His-tagged
proteins were puri¢ed on a NiNTA agarose column
(QIAGEN) and used to immunize rabbits.
2.5. Immunoblot analysis
Five^ten microgram of a total soluble cellular ex-
tract were boiled 5 min in Laemmli bu¡er, electro-
phoresed through 10% SDS-PAGE and electroblot-
ted onto nitrocellulose membranes (Bio-Rad). The
membranes were treated with 5% dry milk in TTBS
(20 mM Tris^HCl pH 7, 50 mM NaCl, 0.1% Tween
20) to inhibit non-speci¢c binding. Anti-IDS antise-
rum was used at a 1:1000 dilution in TTBS. Visual-
ization of antibody binding was carried out with
ECL (Amersham), according to the manufacturer’s
instructions.
2.6. Reverse transcriptase-PCR (RT-PCR)
Total RNA was isolated from COS 7 cells after 48
h transfection by RNeasy extraction kit from Qia-
gen, according to the instructions of the manufac-
turer. 1 Wg of total RNA was reverse-transcribed
by using 2.5 U Moloney murine leukemia virus
(M-MLV) reverse transcriptase and 2.5 WM random
hexamers as primers: reagents were incubated for 10
min at room temperature and 15 min at 42‡C. The
resulting cDNA was ampli¢ed with 2.5 U of Taq
Polymerase (Cetus) and speci¢c primers (100 Wg
each) during 30 cycles of PCR. Each cycle included
denaturation at 95‡C (30 s), re-annealing at 57‡C (20
s) and primer extension at 72‡C (45 s). Sequence
of forward and reverse primers used for ampli¢ca-
tion of speci¢c cDNA is the following: 5P-CTC-
TGAACGTTCTTCTCATC (oligo IDS 5seq), 5P-
TCCCACCGACATGGTCACA (oligo C2).
2.7. Biosynthetic labelling and SDS analysis
Twenty-four hours after transfection, cells were
starved for 1 h with methionine-cysteine-free me-
dium, DMEM (ICN), then labelled for 1 h with
100 WCi of amino acid mixture containing 35S-meth-
ionine^35S-cysteine (Amersham) in the same medium
and chased for 24 and 48 h in DMEM medium
supplemented with 10% FCS. Subsequently, cells
were washed three times with ice-cold PBS and lysed
on ice for 30 min in 500 Wl B-bu¡er (10 mM Tris^
HCl bu¡er pH 7.4, 150 mM NaCl, 1 mM EDTA pH
8) containing 1% Triton X-100. Cell lysates were
clari¢ed by centrifugation at 13 000 rpm, adjusted
to 0.4% SDS, 2% Triton X-100 and incubated over-
night with 1 Wl rabbit anti-IDS antiserum. Immune
complexes were precipitated with 50 Wl protein A-
Sepharose suspension (1:1 in B-bu¡er, 1% Triton
X-100), washed three times with B-bu¡er, 0.4%
SDS, 2% Triton X-100 and analyzed by SDS-
PAGE, followed by £uorography.
2.8. Subcellular fractionation
Three 10 cm culture plates for each of the trans-
fected COS 7 cells were grown for 48 h and then
harvested by trypsin treatment. Cells were pooled
and resuspended in 2 ml of 0.25 M sucrose pH 7.0;
subcellular fractions were then prepared on a 25%
Percoll gradient according to Anson et al. [24] except
that lysis was performed by 20 strokes on ice in tight
¢tting homogenizer. The resulting gradient was col-
lected in 0.5 ml fractions. Fractions were then freeze-
thawed six times to disrupt organelles for lysosomal
enzyme analysis. Each fractionation was performed
twice.
2.9. Immunoquanti¢cation
IDS polypeptide levels were measured with an im-
munoquanti¢cation assay as described by Brooks et
al. [25] with minor modi¢cations. 50 Wl of each sub-
cellular fraction was applied to an ELISA plate (Co-
star 96 wells EIA/RIA plates) by incubating over-
night at 4‡C. Unbound material was aspirated and
the remaining reactive sites blocked with bu¡er A
(0.02 M Tris^HCl pH 7.0; 0.25 M NaCl; 1% (w/v)
ovoalbumin; 0.05% (v/v) Tween 20) for 3 h at room
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temperature. Wells were then treated with 50 Wl of a
1:500 dilution of anti-IDS polyclonal antibody for
three h at room temperature, washed three times in
bu¡er B (0.02 M Tris^HCl pH 7.0; 0.25 M NaCl)
and then incubated with a 1:3000 dilution in bu¡er
A of a peroxidase labelled anti-rabbit immunoglob-
ulin second antibody (Amersham) for 1 h at room
temperature. After three washes in bu¡er B, 200 Wl of
peroxidase substrate (Bio-Rad, ABTS substrate kit)
were added and developed at room temperature for
45 min. Absorbance was measured at 414 nm on a
Bio-Rad ELISA reader. Known concentrations of
pure recombinant IDS protein ranging from 0.05 to
4 Wg/ml were used to construct standard curves for
the quanti¢cation assay.
3. Results
3.1. Enzyme activity of IDS mutants
After introduction of the appropriate nucleotide
changes into wild-type IDS expression vector
pCAGGS by in vitro site-directed mutagenesis,
wild-type and mutant plasmids were transiently
transfected into COS 7 cells by electroporation. Cells
were harvested 48 h post-transfection and total cell
extracts were assayed for IDS activity. Results are
reported in Table 1: untransfected COS 7 cells
showed an average normalized IDS activity of 4.2
U/mg of protein; COS 7 cells transfected with wild-
type IDS cDNA had an activity of 346 U/mg, result-
ing in a 82 fold increase. Cells expressing mutant
cDNAs exhibited greatly reduced activity, ranging
from average values of 10.3^47.6 U/mg protein, i.e.
from about 2.9^13.7% of the wild-type activity, re-
spectively. However, only for mutant R88H residual
Fig. 1. Lineweaver^Burk plot of wild-type and R88H IDS con-
structs measured in transiently transfected COS 7 cell homoge-
nates. 40 Wg of proteins were incubated with various substrate
concentrations at 37‡C. Km and Vmax values were calculated
from Lineweaver^Burk plots.
Table 1
IDS activity of IDS mutants transiently transfected in COS 7 cells
Cell type Experiment 1 Experiment 2 Experiment 3 Average normalized
IDS activityb
(U/mg)IDS
(U/mg)
Luciferase
units
Norm-
alizeda
IDS
(U/mg)
Luciferase
units
Norm-
alizeda
IDS
(U/mg)
Luciferase
units
Norm-
alizeda
Untransfected 5.7 10 422 4.1 4.8 561 210 4.1 4.5 132 621 4.4 4.2 þ 0.2
Wild-type 380.0 7 392 380.0 322.0 474 810 322.0 335.0 128 466 335.0 346.0 þ 31.8
R88H 61.4 10 685 42.6 55.0 652 100 40.1 62.5 134 252 60.1 47.6 þ 12.4
R88P 14.6 49 915 2.16 11.5 419 976 13.1 17.0 138 369 15.7 10.3 þ 9.5
T118I 20.0 11 297 13.7 ^ 887 476 ^ 32.0 125 024 33.0 23.3 þ 13.6
959delT 19.6 8 975 16.2 9.7 972 576 4.7 27.0 96 263 36.0 19.0 þ 14.0
R468Q 12.6 10 250 9.1 21.0 562 545 17.8 37.0 162 072 29.3 18.7 þ 14.3
Note: To control transfection e⁄ciency and variability, all results were normalized by testing luciferase activity after cotransfection
with a luciferase reporter gene vector.
aBy comparison of the luciferase activity of the mutants with the luciferase activity of the wild-type constructs, to correct for transfec-
tion variability.
bAverage of the normalized activity results of three independent experiments.
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activity was higher than 10% of normal in all experi-
ments performed. Thus, kinetic parameters were
evaluated for this mutant protein. As shown in Fig.
1 the apparent Km value for R88H alteration was 133
WM, lower than that found for the normal enzyme,
327 WM, indicating higher substrate a⁄nity. How-
ever, the Vmax value for the mutant enzyme, 0.104
nmol/h, was 24-fold lower than that found for nor-
mal enzyme, 2.5 nmol/h, suggesting that the R88H
mutant protein is less e⁄cient in the turning over the
substrate with respect to the wild-type enzyme. When
IDS activity was tested in the culture medium of cells
transfected with all mutant cDNAs, values appeared
to be near zero, eliminating the possibility of an ex-
tracellular targeting of the mutant enzymes as an
explanation for the low activity found inside cells
(data not shown).
3.2. Immunoblot analysis of mutant IDS polypeptides
The presence of IDS polypeptides in transfected
COS 7 cell extracts was determined by immunoblot
analysis, using an anti-IDS serum (Fig. 2). Cells
transfected with the parental pCAGGS vector did
not produce cross-reacting protein. Cells expressing
the normal IDS cDNA presented two major bands:
90 and 62 kDa, related to the precursor/intermediate
forms of the enzyme and a minor band of 55 kDa
related to the mature form [5,6]. The same results
were found in cells transfected with the missense mu-
tations R88H, R88P, T118I and R468Q. In contrast,
in cells transfected with the construct containing the
959delT mutation, no protein form was detectable.
To examine whether a transcript was present, RT-
PCR experiments were performed. For this purpose,
total RNA from COS 7 cells transfected with
959delT and T118I constructs were reverse-tran-
scribed using two oligonucleotides present on coding
cDNA (see Section 2); a positive control containing
total RNA from wild-type transfected cells, and neg-
ative controls containing H2O or total RNA from
cells transfected with parental vector were also
used. As shown in Fig. 3, a fragment of the expected
size (297 bp), representing the IDS mRNA, was am-
pli¢ed in all examined samples resulting identical in
the wild-type (lane 1) and in the two mutants tested
(lanes 2 and 3); no band was visible in the negative
controls (lanes 4 and 5). This result implies that the
cDNA carrying the 959delT mutation undergoes
transcription; the absence of cross-reacting material
on Western blot, is most likely due to loss of anti-
body recognition domain; in fact, the single base
deletion 959delT results in a premature stop codon
Fig. 3. RT-PCR analysis of total RNA from COS 7 cells transi-
ently transfected with pCAGGS constructs. 1 Wg total RNA
was reverse transcribed in a total volume of 20 Wl. PCR reac-
tion was performed in a total volume of 100 Wl. Samples were
then subjected to electrophoresis on 1.2% agarose gel and
stained with ethidium bromide. Lane M: 100 bp DNA ladder;
lane 1: COS 7 cells transfected with wild-type cDNA; lane 2:
COS 7 cells transfected with T118I cDNA; lane 3: COS 7 cells
transfected with 959delT cDNA; lane 4: COS 7 cells trans-
fected with parental cDNA; lane 5: negative control (no RNA
was added in RT reaction). The length of the IDS fragment
ampli¢ed is indicated on the right.
Fig. 2. Immunoblot analysis of COS 7 cell homogenates transi-
ently transfected with pCAGGS constructs. Each pCAGGS
construct (10 Wg) was transfected into COS 7 cells ; a mock
transfection was carried out without the addition of DNA. The
mass (in kDa) of the molecular weight markers are indicated
on the left.
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lacking the C-terminal region of the IDS protein
against which the antibody was made.
3.3. Pulse-chase labelling of IDS mutants
After metabolic labelling for 1 h, COS 7 cells
transfected with the wild-type IDS expression vector,
produced three polypeptides of 90, 62 and 45 kDa,
corresponding to precursor, intermediate and mature
forms of the IDS enzyme, respectively (Fig. 4, ¢rst
lane). After labelling for 1 h followed by 24 h chase,
the 90 kDa precursor form was converted into the 45
kDa mature polypeptide (Fig. 4, second lane). When
COS 7 cells were transfected with the IDS cDNAs,
carrying the four missense mutations and subjected
to the same labelling procedure, all the IDS mutants
showed apparently normal maturation and stability.
Results are shown in Fig. 4 (lanes 3^10). When the
chase time was prolonged to 48 h (data not shown),
no signi¢cant di¡erence was evident, i.e. conversion
was not total, but the precursor form was still
present, probably due to over-expression.
3.4. Subcellular fractionation and
immunoquanti¢cation
Post-nuclear supernatants from transfected cells
were subfractionated on 25% Percoll gradients (see
Section 2). Fractions from cells transfected with wild-
Fig. 5. Subcellular fractionation of the transfected COS 7 cells
by Percoll density gradient centrifugation. Cells were transfected
and harvested after 48 h; the postnuclear supernatant was then
subjected to 25% Percoll density centrifugation. L-Hexosamini-
dase and IDS activities (for cells transfected with wild-type IDS
cDNA) and IDS polypeptide levels (for all transfected cells)
were determined as described in Section 2. Red line and num-
bers represent IDS activity expressed as U/ml; blue line and
numbers represent L-hexosaminidase activity expressed as nmol/
min/ml. Black lines represent IDS polypeptide levels, as deter-
mined by ELISA immunoquanti¢cation.
Fig. 4. Pulse-chase labeling of COS 7 cell homogenates transi-
ently transfected with pCAGGS constructs. COS 7 cells were
labeled with 35S-methionine and 35S-cysteine mixture for 1 h
and harvested immediately or after chase of 24 h in unlabeled
medium. Cells were then immunoprecipitated with anti-IDS
antibodies and analyzed by SDS-PAGE and £uorography. Ex-
posure time was 6 days. Bands of 197, 117, 89 and 52 kDa cor-
responding to molecular weight markers are arrowed on the
right.
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type IDS were assayed for L-hexosaminidase and
IDS activities (Fig. 5, blue and red line, respectively).
The wild-type IDS co-fractionated with L-hexosa-
minidase associated with high-density organelles
characteristic of lysosomes (Fig. 5: fractions 30^35).
Fractions from all transfected cells were immuno-
quanti¢ed for IDS protein (Fig. 5, black line) using
the standard curve reported in Fig. 6. Results on IDS
recovered in lysosomal fractions are reported in Ta-
ble 2. As shown from Fig. 5 and Table 2, a high
proportion of the R88H, R88P and R468Q polypep-
tides were detected in the lower-density fractions
(Fig. 5, fractions 9^15), the amounts associated
with lysosomes being 55%, 47% and 50%, respec-
tively, of that found for wild-type. T118I polypep-
tides were distributed in early vacuolar compart-
ments (Fig. 5, fractions 10^28), with 78% amount
in the lysosomes.
4. Discussion
We characterized ¢ve of the IDS mutations previ-
ously reported on Italian Hunter patients [15,16].
Mutations at position 88 were investigated since
this arginine residue belongs to the highly conserved
pentapeptide CXPSR [26^28] where cysteine modi¢-
cation to formylglycine is required for sulfatase ac-
tivity [29,30]. Within this motif, Cys-84 and Pro-86
residues were previously studied through in vitro ex-
pression [10,31]. Residue 88 is an evolutionary con-
served amino acid, as shown from comparison of
human and murine IDS gene [32], and represents a
mutational ‘hot spot’ for the IDS gene [33]. R88H
mutation was found in an aborted fetus [16] from a
family where the index case, T.P., was previously
classi¢ed as severe; R88P mutation was identi¢ed
in a unrelated severe subject, F.N. [16]. In cells trans-
fected with R88H mutant cDNA a 13.7% residual
activity resulted with a Km value 2.5-fold lower
than that found for normal enzyme, thus indicating
a higher a⁄nity for the arti¢cial substrate. This did
not correlate with the severe phenotype reported in
that family. On the other hand Rathmann et al. [33]
referred a severe R88H patient while Gort et al. [34]
reported an intermediate phenotype associated with
the same alteration. This discordance led us to search
for additional information on the clinical symptoms
manifested by patient T.P. The clinician involved in
this case reported that the subject, classi¢ed severe
on the basis of his mental retardation, showed very
mild skeletal alterations, with no joint sti¡ness. Since
a low enzyme activity is enough to allow a normal
phenotype in most lysosomal diseases [35], the 13.7%
residual activity, the Km data and the 45 kDa lyso-
somal mature form observed in pulse-chase experi-
ments can explain the ‘attenuated’ skeletal phenotype
of this patient. Subcellular distribution studies in
Table 2
Immunoquanti¢cation after subcellular fractionation
Cell type Total (ng) Lysosomesa Normalized Percent
Wild-type 3588 793 793 100
R88H 2539 314 439 55
R88P 2197 237 379 47
T118I 3283 568 619 78
R468Q 3372 375 397 50
aThis column reports the amount (ng) recovered in lysosomal fractions (30^35).
Fig. 6. Standard curve for IDS immunoquanti¢cation. A stan-
dard curve (A) was generated for the IDS immunoquanti¢ca-
tion assay by ELISA of 0.05^4 Wg/ml solutions of recombinant
IDS protein. Samples were assayed in triplicate and expressed
as mean þ S.D. (B) Represents the background activity of the
assay.
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COS cells expressing R88H mutation, however,
showed evidence for retention of the polypeptides
within early vacuolar compartment (fractions 9^15),
with only 55% of the mutant protein reaching the
lysosomal fractions (fractions 30^35). This suggests
that substitution of the arginine residue at codon 88
with an histidine residue leads to incorrect folding of
the protein.
The second mutation analyzed, R88P, which sub-
stitutes a positively charged arginine with the rigid,
neutral amino acid proline leads to very low residual
activity after transfection (2.9% of the wild-type).
Although Western blot and maturation studies sug-
gested an apparently normal maturation, incorrect
folding and targeting was evident for this mutation
since only 47% of the mutant polypeptide was able to
reach the lysosomes. The introduction of a proline
residue in that position probably perturbs the molec-
ular interactions and the structural architecture of
the active site. These data are in agreement with
the severe phenotype associated with patient F.N.
[16].
The T118I substitution, converting a threonine to
an isoleucine residue, changes an amino acid con-
served among human and murine sulfatases. Transi-
ent expression of this mutation in COS 7 cells
showed low residual activity (6.7% of the normal
control), with an apparently normal maturation
(Western blot and pulse-chase analyses) and a lyso-
somal localization corresponding to 78% of the wild-
type enzyme. All these observations may explain the
mild phenotype observed in our patient.
For the T deletion at nucleotide 959, associated to
a severe phenotype, the mutation results in a prema-
ture termination of the polypeptide. We have data
concerning activity (5.5% of wild-type) but no data
concerning maturation or enzyme localization, since
the antibody would not recognize the truncated pro-
tein. RT-PCR experiments, however, ruled out the
possibility of the absence of RNA synthesis.
Missense mutation R468Q involved the ‘hot spot’
468 arginine residue, replaced by glutamine; a very
low activity was found after transfection (5.4% of
normal), an apparently normal maturation was ob-
served from immunoblot and labelling experiments,
but an incorrect localization was evident from sub-
cellular fractionation with only 50% of the mutant
polypeptides reaching the lysosomes. These ¢ndings
correlate with the severe Hunter phenotype of our
patient [15] as well as of patients, with the same
mutation, reported by others [33,36].
It is interesting to note that none of the point
mutations examined here (R88H, R88P, T118I, and
R468Q) prevented maturation of IDS. Our results
are similar to those obtained by Rommerskirch and
von Figura [30] on MSD cells where the absence of
conversion of the cysteine residue to formylglycine
did not prevent maturation of arylsulfatase A pre-
cursor form. They are consistent also with results
obtained by Brooks et al. [37] when cysteine 91 res-
idue of arylsulfatase B was mutated to a serine res-
idue or to those reported by Millat et al. [31] for
cysteine 84 of IDS substituted to a threonine residue.
In contrast, P86L and P86R mutations did not result
in mature IDS forms [10] showing that proline 86
residue is essential for IDS processing. Our subcellu-
lar localization studies provided evidence of retention
of signi¢cant fractions of all four mutant proteins
within early vacuolar compartments, with only par-
tial targeting of polypeptides to lysosomes. We con-
clude that residues 88, 118 and 468 appear not essen-
tial for IDS processing but do contribute to the IDS
conformation essential for normal transport from the
early vacuolar compartment to lysosomes.
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